Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type

Guidance programme 1 selected

Guidance programme

Area of interest

Showing 301 to 310 of 899

TitleReference numberPublishedLast updated
Nivolumab with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinomaTA857
Lenvatinib with pembrolizumab for untreated advanced renal cell carcinomaTA858
Upadacitinib for treating moderately to severely active ulcerative colitisTA856
Avatrombopag for treating primary chronic immune thrombocytopeniaTA853
Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancerTA851
Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more treatmentsTA852
Esketamine nasal spray for treatment-resistant depressionTA854
Cabozantinib for previously treated advanced hepatocellular carcinomaTA849
Amivantamab for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapyTA850
Cemiplimab for untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer (terminated appraisal)TA848

Results per page

  1. 10
  2. 25
  3. 50
  4. All